Gemcitabine, docetaxel, and bevacizumab in relapsed and refractory pediatric sarcomas.

ABSTRACT

BACKGROUND: The outcome for patients with relapsed and refractory pediatric sarcomas remains dismal. Novel agents are needed to improve overall survival in these patients. OBSERVATIONS We present 3 patients with relapsed/refractory sarcomas treated with gemcitabine, docetaxel, and bevacizumab in 3-week cycles. The combination was well tolerated with minimal toxicity. Two patients had a partial response and the third patient had stable disease for >6 months. CONCLUSIONS: These results are limited by small patient numbers but this strategy should be evaluated in prospective clinical trials.